Search Result

Results for "

protein+aggregation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (12) Autophagy (4) Biochemical Assay Reagents (2) Cholinesterase (ChE) (5) Dopamine Receptor (1) Drug Derivative (1) Ferroptosis (1) Fungal (1) GSK-3 (3) HDAC (1) HSP (7) Huntingtin (2) Isotope-Labeled Compounds (1) JNK (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) NF-κB (1) NOD-like Receptor (NLR) (1) Prion Protein (1) PROTACs (1) Proteasome (2) Reactive Oxygen Species (ROS) (2) Reference Standards (2) SOD (1) Tau Protein (10) Trk Receptor (1) α-synuclein (3)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (6) Metabolic Disease (5) Neurological Disease (35)

By Targets:

Amyloid-β (12)

Autophagy (4)

Biochemical Assay Reagents (2)

Cholinesterase (ChE) (5)

Dopamine Receptor (1)

Drug Derivative (1)

Ferroptosis (1)

Fungal (1)

GSK-3 (3)

HDAC (1)

HSP (7)

Huntingtin (2)

Isotope-Labeled Compounds (1)

JNK (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

NF-κB (1)

NOD-like Receptor (NLR) (1)

Prion Protein (1)

PROTACs (1)

Proteasome (2)

Reactive Oxygen Species (ROS) (2)

Reference Standards (2)

SOD (1)

Tau Protein (10)

Trk Receptor (1)

α-synuclein (3)

By Research Areas:

Cancer (5)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (6)

Metabolic Disease (5)

Neurological Disease (35)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106443A

Arimoclomol maleate 5 Publications Verification BRX-220	HSP	Neurological Disease Metabolic Disease Inflammation/Immunology
Arimoclomol maleate (BRX-220) is an orally active co-inducer of heat shock proteins (HSP) . Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .Arimoclomol maleate can be used for the study of Niemann–Pick disease type C.

HY-106443

Arimoclomol 5 Publications Verification BRX-220 free base	HSP	Neurological Disease Metabolic Disease Inflammation/Immunology
Arimoclomol (BRX-220 free base) is an orally active co-inducer of heat shock proteins (HSP). Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system.Arimoclomol can be used for the study of Niemann–Pick disease type C. Arimoclomol can cross the blood-brain barrier and can be used in research on Niemann-Pick disease type C .

HY-19948

Leucomethylene blue mesylate 5+ Cited Publications TRx0237 mesylate; Methylene blue leuco base mesylate	Tau Protein	Neurological Disease
Leucomethylene blue (TRx0237) mesylate, an orally active second-generation tau protein aggregation inhibitor (K_i of 0.12 μM), could be used for the study of Alzheimer's Disease. Leucomethylene blue mesylate is a common reduced form of Methylene Blue, Methylene Blue is a member of the thiazine class of dyes .

HY-P4808

PHF6	Amyloid-β Autophagy	Neurological Disease
PHF6 (VQIVYK) is a self-assembly sequence capable of initiating the full-length tau protein aggregation and is mapped to the third microtubule-binding repeat region of the tau protein .

HY-106443B

Arimoclomol citrate 5 Publications Verification BRX-220 citrate	HSP	Neurological Disease Metabolic Disease Inflammation/Immunology
Arimoclomol citrate (BRX-220 citrate) is an orally active co-inducer of heat shock proteins (HSP) . Arimoclomol citrate protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system . Arimoclomol citrate can be used for the study of Niemann–Pick disease type C.

HY-W010041

Scyllo-Inositol	α-synuclein Amyloid-β	Neurological Disease
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-137441

Icapamespib 1 Publications Verification PU-HZ151	HSP	Neurological Disease Cancer
Icapamespib (PU-HZ151; PU-AD) is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .

HY-P9995

Posdinemab JNJ-63733657	Tau Protein	Neurological Disease
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .

HY-N1414

(E)-3',6-Disinapoylsucrose	Trk Receptor NF-κB Amyloid-β	Neurological Disease
(E)-3',6-Disinapoylsucrose is an orally active, blood-brain barrier permeable neuroprotective agent that inhibits Aβ protein aggregation. (E)-3',6-Disinapoylsucrose exerts anxiolytic, anti-inflammatory and cognitive-enhancing effects. (E)-3',6-Disinapoylsucrose regulates the TrkB/BDNF signaling pathway, inhibits the expression of NF-κB p65, reduces pro-inflammatory cytokine levels, and alleviates neuronal damage. (E)-3',6-Disinapoylsucrose also enhances the functions of central 5-HT and noradrenergic systems, thereby improving spatial learning and memory abilities and reducing anxiety-like behaviors. (E)-3',6-Disinapoylsucrose can be used for the research of related diseases such as Alzheimer's disease, depression, memory impairment and anxiety disorder .

HY-153430

*Aβ/tau aggregation-IN-3*	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC₅₀ of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity .

HY-P3414A

Proteasome-activating peptide 1 TFA 3 Publications Verification	Proteasome	Neurological Disease
Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis .

HY-P4808A

PHF6 TFA	Amyloid-β Autophagy	Neurological Disease
PHF6 (VQIVYK) TFA is a self-assembly sequence capable of initiating the full-length tau protein aggregation. PHF6 TFA is mapped to the third microtubule-binding repeat region of the tau protein .

HY-137441A

Icapamespib hydrochloride 1 Publications Verification PU-HZ151 hydrochloride	HSP	Neurological Disease Cancer
Icapamespib (PU-HZ151; PU-AD) hydrochloride is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib hydrochloride can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib hydrochloride can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib hydrochloride can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .

HY-148629

GDC-0134	JNK	Neurological Disease
GDC-0134 (RG6000) is a modulator targeting dual leucine zipper kinase (DLK) that can cross the blood-brain barrier. By inhibiting the kinase activity of DLK, GDC-0134 blocks the activation of the downstream JNK signaling pathway, suppresses DLK-dependent retrograde signal transduction of axon-to-soma degeneration, and exerts neuroprotective activity. GDC-0134 reduces TDP-43 protein aggregation and decreases the degree of neuromuscular junction denervation in motor neurons. GDC-0134 can be used in the research of amyotrophic lateral sclerosis (ALS), Alzheimer's disease and other DLK-related neurodegenerative diseases .

HY-W392413

Glutathione monoethyl ester	Drug Derivative Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Glutathione monoethyl ester is a glutathione derivative that can be transported into cells and hydrolyzed into glutathione. Glutathione monoethyl ester downregulates the gene expression of TEN1 and CTC1 while upregulating TERT expression. Glutathione monoethyl ester enhances telomerase activity, promotes proliferation and differentiation in aged bone marrow stromal cells, while elevating glutathione levels and reducing oxidative stress, protein aggregation and cell death in motor neuronal cells. Glutathione monoethyl ester confers broad multi-organ protection against cerebral ischemia, renal injury, liver damage, and pancreatitis. Glutathione monoethyl ester can be used for the research of amyotrophic lateral sclerosis, stroke, acute renal failure, liver injury, and acute pancreatitis .

HY-153427

*Tau protein aggregation-IN-1*	Tau Protein	Neurological Disease
Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies .

HY-W011831

NDSB-256 3-(Benzyldimethylammonio)propane-1-sulfonate; PDA	Biochemical Assay Reagents	Others
NDSB-256 is a non-stain remover sulfabetaine. NDSB-256 prevents protein aggregation and promotes denaturation of chemically and thermally denatured proteins .

HY-148901

CMB-087229	SOD	Neurological Disease
CMB-087229 is a mutant superoxide dismutase 1 (SOD1) protein aggregation inhibitor with IC₅₀ of 67 nM, which can be used in the research of amyotrophic lateral sclerosis .

HY-P3414

Proteasome-activating peptide 1	Proteasome	Neurological Disease
Proteasome-activating peptide 1 is a peptide, which increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis .

HY-125197

BRD5631	Autophagy	Inflammation/Immunology
BRD5631 is an autophagy enhancer, enhances autophagy through an mTOR-independent pathway. BRD5631 affects several cellular disease phenotypes previously linked to autophagy, including protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production .

HY-W835959

ACI-3024	Tau Protein	Neurological Disease
ACI-3024 is an an orally active and highly selective Tau protein aggregation inhibitor. ACI-3024 decrease the β-sheet content and seeding properties of pathological Tau from different Tauopathies, leading to a significant rescue of the Tau-induced neurodegeneration and neuroinflammation in a cellular model. ACI-3024 is promising for research of neurodegenerative diseases .

HY-W127622

NDSB 256-4T 3-(4-(tert-Butyl)pyridinio)-1-propanesulfonate	Biochemical Assay Reagents	Others
NDSB 256-4T is a non-washing sulfabetaine compound. NDSB-256-4T prevents protein aggregation and promotes protein folding by interacting with early folding intermediates .

HY-P10818

Polyglutamine binding peptide 1	Huntingtin	Neurological Disease
Polyglutamine binding peptide 1 (QBP1) is a peptide inhibitor of polyglutamine (polyQ). Polyglutamine binding peptide 1 inhibits polyQ protein aggregation in vitro and suppresses polyQ-induced cell death in cell culture .

HY-146135

*Tau-aggregation-IN-1*	Microtubule/Tubulin Dopamine Receptor	Neurological Disease
Tau-aggregation-IN-1 (Compound D-519) is a tau441 protein aggregation inhibitor with an IC₅₀ of 21 µM. Tau-aggregation-IN-1 is also a dopamine D₂ and D₃ receptor agonist .

HY-109116A

Hydromethylthionine dihydrobromide Leukomethylene blue dihydrobromide; LMTM dihydrobromide	Tau Protein	Neurological Disease
Hydromethylthionine dihydrobromide (Leukomethylene blue dihydrobromide) is a potent inhibitor of TAU protein aggregation. Hydromethylthionine dihydrobromide reduces neurodegeneration by interacting with TAU proteins and preventing them from forming neurotoxic aggregates. Hydromethylthionine dihydrobromide can be used in the study of Alzheimer's disease and other TAU related disorders .

HY-179377

Aha1/Hsp90-IN-2	HSP Tau Protein	Neurological Disease
Aha1/Hsp90-IN-2 is a selective inhibitor of the Hsp90/Aha1 interaction, with its IC₅₀ being 1.46 μM. Aha1/Hsp90-IN-2 inhibits the activation of Hsp90 ATPase activity mediated by Aha1 by specifically blocking the binding of Hsp90 to Aha1, thereby reducing tau protein aggregation. Aha1/Hsp90-IN-2 can be used for the study of neurodegenerative diseases, such as Alzheimer's disease .

HY-W741557

Griseofulvic Acid (±)-Griseofulvic acid	Fungal	Infection
Griseofulvic acid is a metabolite of the antifungal Griseofulvin (HY-17583). It induces protein aggregation and tubulin polymerization in cell-free assays.

HY-164539

TMU 35435	HDAC Autophagy	Cancer
TMU 35435 is a histone deacetylase (HDAC) inhibitor. TMU-35435 inhibits the NHEJ pathway through ubiquitination of DNA-dependent protein kinase catalytic subunit (DNA-PKcs). In addition, TMU 35435 enhances radiosensitivity by inducing misfolded protein aggregation and autophagy in TNBC .

HY-N10352

4-epi-Withaferin A	Others	Cancer
4-epi-Withaferin A (compound 28) is the analogue of Withaferin A. 4-epi-Withaferin A enhances cytotoxicity and cytoprotective heat-shock-inducing activity (HSA). 4-epi-Withaferin A has the potential for the research of protein aggregation-associated diseases by stimulating cellular defense mechanisms .

HY-161448

*Tau-aggregation-IN-3*	Tau Protein	Neurological Disease
Tau-aggregation-IN-3 (compound 9) a Tau protein aggregation inhibitor (TAI). Tau-aggregation-IN-3 shows activity in cell-based aggregation inhibition experiments (EC₅₀=4.816 μM). Tau-aggregation-IN-3 can be used in Alzheimer's disease research .

HY-P10534

ccβ	Prion Protein	Infection Neurological Disease
CCβ is a simple 17-amino acid peptide designed in research. CCβ is able to mimic the conformational transition of proteins from α-helix to β-sheet, which is a key step in the aggregation of proteins associated with many diseases, such as Alzheimer's disease and prion disease. CCβ can be used to study diseases related to protein aggregation .

HY-149273

hBChE-IN-1	Cholinesterase (ChE) Amyloid-β Tau Protein	Neurological Disease
hBChE-IN-1 (compound 4), a quinolizidinyl derivative, is a potent hBChE inhibitor (IC₅₀=7 nM) and highly selective over hAChE. hBChE-IN-1 shows inhibitory activity against tau and Aβ₄₀ protein aggregation, with IC₅₀ values of 20 and 4.3 μM, respectively. hBChE-IN-1 can be used for Alzheimer's disease research .

HY-174272

GSK-3β inhibitor 27	GSK-3 Amyloid-β	Neurological Disease
GSK-3β inhibitor 27 (Compound 1c) is a reversible and competitive GSK-3β inhibitor with an IC₅₀ value of 2.2 μM. GSK-3β inhibitor 27 inhibits tau hyperphosphorylation, reduces Aβ protein aggregation and possesses metal chelation and neuroprotective potential. GSK-3β inhibitor 27 is promising for research of neurodegenerative diseases (such as Alzheimer’s disease) .

HY-170417

hAChE/hBuChE/GSK-3β-IN-1	Cholinesterase (ChE) GSK-3	Neurological Disease
hAChE/hBuChE/GSK-3β-IN-1 (Compound 6c) is a BBB-penetrable and multi-target anti-Alzheimer's disease compound. hAChE/hBuChE/GSK-3β-IN-1 is the inhibitors of hAChE (IC₅₀: 28.88 nM), hBuChE (IC₅₀: 131.90 nM) and GSK-3β (IC₅₀: 51.42 nM). hAChE/hBuChE/GSK-3β-IN-1 is the tau and Aβ protein aggregation inhibitors .

HY-175658

AChE/BChE-IN-29	Cholinesterase (ChE) Amyloid-β Tau Protein	Neurological Disease
AChE/BChE-IN-29 is an AChE/BChE inhibitor. AChE/BChE-IN-29 exhibits balanced dual cholinesterase inhibitory activity with IC₅₀ values of 2.1 μM for Electrophorus electricus AChE (eeAChE) and 6.3 μM for equine serum butyrylcholinesterase (eqBChE). AChE/BChE-IN-29 effectively inhibits amyloid-β (Aβ₄₂) aggregation and tau protein aggregation in E. coli cell models. AChE/BChE-IN-29 can be used for the study of Alzheimer’s disease (AD) .

HY-W010041R

Scyllo-Inositol (Standard)	Reference Standards α-synuclein Amyloid-β	Neurological Disease
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-155365

hAChE-IN-5	Cholinesterase (ChE) GSK-3 Amyloid-β	Neurological Disease
hAChE-IN-5 (compound 49) is a potent hAChE and hBuChE inhibitor with IC₅₀ values of 0.17 μM and 0.17 μM, respectively. hAChE-IN-5 shows potent GSK3β inhibition with an IC₅₀ value of 0.21 μM. hAChE-IN-5 is used as tau protein aggregation and Aβ1-42 self-aggregation inhibitor. hAChE-IN-5 can bind virtually with the PAS affecting Aβ aggregation, thus preventing Aβ-dependent neurotoxicity. hAChE-IN-5 can penetrate BBB and has the potential for multi-targeted anti-Alzheimer's agents research .

HY-159898

AChE/BChE-IN-23	Cholinesterase (ChE) Amyloid-β Tau Protein NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) Mitochondrial Metabolism	Neurological Disease
AChE/BChE-IN-23 (Compound 6e) is an AChE/BChE inhibitor (IC₅₀: 0.91 μM, 1.19 μM and 1.01 μM for hAChE, eq BChE and hBChE, respectively). AChE/BChE-IN-23 has antioxidant activity and inhibits Aβ1-42 and Tau protein aggregation. AChE/BChE-IN-23 also inhibits microglial activation by reducing ROS release and mitochondrial injury. AChE/BChE-IN-23 suppresses NLRP3 inflammasome and pro-inflammatory cytokines in human microglial cells. AChE/BChE-IN-23 also reverses the Scopolamine (HY-N0296)-induced memory impairment in mice model .

HY-145858

Chalcones A-N-5	Ferroptosis	Cancer
Chalcones A-N-5 is a trihydroxy chalcone derivative compound. Chalcones A-N-5 doesn’t show cytotoxicity at the concentration lower than 100 µM (with IC₅₀ > 1 mM), but has a significant effect on promoting cell proliferation. Chalcones A-N-5 potentially promotes neuronal cell growth in the damaged brain tissue. Chalcones A-N-5 also inhibits ferroptosis induced by RSL or erastin and reduces the lipid peroxidation levels induced by Aβ1-42 protein aggregation. Chalcones A-N-5 is a promising molecular skeleton candidate for further development of lead compound for in vivo test to research AD .

HY-W707693

Scyllo-Inositol-d6	Isotope-Labeled Compounds Amyloid-β α-synuclein	Neurological Disease
Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-106443AR

Arimoclomol maleate (Standard) BRX-220 (Standard)	Reference Standards HSP	Neurological Disease Metabolic Disease Inflammation/Immunology
Arimoclomol maleate (Standard) is the analytical standard of Arimoclomol maleate (HY-106443A). This product is intended for research and analytical applications. Arimoclomol maleate (BRX-220) is an orally active co-inducer of heat shock proteins (HSP) . Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .Arimoclomol maleate can be used for the study of Niemann–Pick disease type C.

HY-181879

PROTAC mHTT Degrader-1	PROTACs Huntingtin	Neurological Disease
PROTAC mHTT Degrader-1 is a blood-brain barrier-penetrant mutant huntingtin (mHTT) PROTAC degrader. PROTAC mHTT Degrader-1 specifically recognizes pathogenic mHTT aggregates and recruits Cereblon (CRBN), thereby inducing ubiquitination and proteasomal degradation of mHTT. PROTAC mHTT Degrader-1 alleviates mHTT-induced cytotoxicity and neuroinflammation. In the R6/2 Huntington's disease mouse model, PROTAC mHTT Degrader-1 reduces cerebral protein aggregation levels and improves body weight, motor coordination and survival rate of animals. PROTAC mHTT Degrader-1 can be used for research on PROTAC therapies for Huntington's disease and other neurodegenerative diseases .

Cat. No.	Product Name

HY-L133

Cuproptosis Compound Library	403 compounds
Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis". The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis. Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism. Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis. MCE supplies a unique collection of 403 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.

Cuproptosis Compound Library

403 compounds

Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis".

The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis.

Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism.

Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis.

MCE supplies a unique collection of 403 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.

Cat. No.	Product Name	Type

HY-19948

Leucomethylene blue mesylate 5+ Cited Publications TRx0237 mesylate; Methylene blue leuco base mesylate	Fluorescent Dye
Leucomethylene blue (TRx0237) mesylate, an orally active second-generation tau protein aggregation inhibitor (K_i of 0.12 μM), could be used for the study of Alzheimer's Disease. Leucomethylene blue mesylate is a common reduced form of Methylene Blue, Methylene Blue is a member of the thiazine class of dyes .

Cat. No.	Product Name	Type

HY-W011831

NDSB-256 3-(Benzyldimethylammonio)propane-1-sulfonate; PDA	Biochemical Assay Reagents
NDSB-256 is a non-stain remover sulfabetaine. NDSB-256 prevents protein aggregation and promotes denaturation of chemically and thermally denatured proteins .

HY-W127622

NDSB 256-4T 3-(4-(tert-Butyl)pyridinio)-1-propanesulfonate	Biochemical Assay Reagents
NDSB 256-4T is a non-washing sulfabetaine compound. NDSB-256-4T prevents protein aggregation and promotes protein folding by interacting with early folding intermediates .

Cat. No.	Product Name	Target	Research Area

HY-P4808

PHF6	Amyloid-β Autophagy	Neurological Disease
PHF6 (VQIVYK) is a self-assembly sequence capable of initiating the full-length tau protein aggregation and is mapped to the third microtubule-binding repeat region of the tau protein .

HY-P3414A

Proteasome-activating peptide 1 TFA 3 Publications Verification	Proteasome	Neurological Disease
Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis .

HY-P4808A

PHF6 TFA	Amyloid-β Autophagy	Neurological Disease
PHF6 (VQIVYK) TFA is a self-assembly sequence capable of initiating the full-length tau protein aggregation. PHF6 TFA is mapped to the third microtubule-binding repeat region of the tau protein .

HY-P3414

Proteasome-activating peptide 1	Proteasome	Neurological Disease
Proteasome-activating peptide 1 is a peptide, which increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis .

HY-P10818

Polyglutamine binding peptide 1	Huntingtin	Neurological Disease
Polyglutamine binding peptide 1 (QBP1) is a peptide inhibitor of polyglutamine (polyQ). Polyglutamine binding peptide 1 inhibits polyQ protein aggregation in vitro and suppresses polyQ-induced cell death in cell culture .

HY-122297A

H-Arg-Phe-OH TFA	Peptides	Others
H-Arg-Phe-OH TFA is an amphipathic peptide. H-Arg-Phe-OH TFA has the ability to induce native-like protein aggregation. H-Arg-Phe-OH TFA can induce aggregation of the neutral model protein yeast alcohol dehydrogenase (ADH) .

HY-122297

H-Arg-Phe-OH	Peptides	Others
H-Arg-Phe-OH is an amphipathic peptide. H-Arg-Phe-OH has the ability to induce native-like protein aggregation. H-Arg-Phe-OH can induce aggregation of the neutral model protein yeast alcohol dehydrogenase (ADH) .

HY-P10534

ccβ	Prion Protein	Infection Neurological Disease
CCβ is a simple 17-amino acid peptide designed in research. CCβ is able to mimic the conformational transition of proteins from α-helix to β-sheet, which is a key step in the aggregation of proteins associated with many diseases, such as Alzheimer's disease and prion disease. CCβ can be used to study diseases related to protein aggregation .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9995

Posdinemab JNJ-63733657	Tau Protein	Neurological Disease
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W010041

Scyllo-Inositol	Natural Products Endogenous metabolite Source Classification	α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N1414

(E)-3',6-Disinapoylsucrose	Structural Classification Simple Phenylpropanols Polygalaceae Phenols Polyphenols Phenylpropanoids Plants Polygala tenuifolia Willd. Source Classification	Trk Receptor NF-κB Amyloid-β
(E)-3',6-Disinapoylsucrose is an orally active, blood-brain barrier permeable neuroprotective agent that inhibits Aβ protein aggregation. (E)-3',6-Disinapoylsucrose exerts anxiolytic, anti-inflammatory and cognitive-enhancing effects. (E)-3',6-Disinapoylsucrose regulates the TrkB/BDNF signaling pathway, inhibits the expression of NF-κB p65, reduces pro-inflammatory cytokine levels, and alleviates neuronal damage. (E)-3',6-Disinapoylsucrose also enhances the functions of central 5-HT and noradrenergic systems, thereby improving spatial learning and memory abilities and reducing anxiety-like behaviors. (E)-3',6-Disinapoylsucrose can be used for the research of related diseases such as Alzheimer's disease, depression, memory impairment and anxiety disorder .

HY-N10352

4-epi-Withaferin A	Classification of Application Fields Withania somnifera Plants Solanaceae Disease Research Fields Steroids Cancer Source Classification	Others
4-epi-Withaferin A (compound 28) is the analogue of Withaferin A. 4-epi-Withaferin A enhances cytotoxicity and cytoprotective heat-shock-inducing activity (HSA). 4-epi-Withaferin A has the potential for the research of protein aggregation-associated diseases by stimulating cellular defense mechanisms .

HY-W010041R

Scyllo-Inositol (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

Cat. No.	Product Name	Chemical Structure

HY-W707693

Scyllo-Inositol-d6

Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

protein+aggregation

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products